Skip to main content
. Author manuscript; available in PMC: 2024 Dec 28.
Published in final edited form as: Addiction. 2023 Jul 19;118(11):2203–2214. doi: 10.1111/add.16289

TABLE 1.

Patient characteristics for FY18 Veterans Health Administration patients with opioid use disorder with and without opioid overdose (n = 66 513).

Characteristic OD cohort (n = 1413) Non-OD cohort (n = 65 100) Standardized difference
Demographicsa
 Sex, n (%)
  Female  108 (7.6)   5007 (7.7)  0.002
 Age at overdose, mean (SD)  51.6 (15.1)   52.4 (14.3)  0.053
 Race, n (%)
  Black  249 (17.6) 12 140 (18.6)  0.027
  White 1086 (76.9) 48 941 (75.2)  0.039
  Other   44 (3.1)   2070 (3.2)  0.004
 Ethnicity, Hispanic, n (%)   78 (5.5)   3759 (5.8)  0.011
 Marital status, n (%)
  Never married  373 (26.5) 15 042 (23.5)  0.068
  Married  401 (28.5) 20 819 (32.6)  0.090
  Separated  108 (7.7)   4968 (7.8)  0.004
  Divorced  469 (33.3) 20 980 (32.9)  0.009
  Widowed   56 (4)   1979 (3.1)  0.047
 Geographic region, n (%)
  Urban 1085 (77)    47 125 (72.9)  0.095
  Rural  318 (22.6) 17 018 (26.3)  0.087
  Highly rural    7 (0.5)   536 (0.83)  0.041
  Territory     0 (0)      6 (0.01)  0.014
 ≥ 50% VA service-connected disability, n (%)  703 (49.9) 28 420 (43.9)  0.120
Clinical
 Elixhauser comorbidities, mean (SD)  5.6 (3.3)      4 (2.7) −0.543
 RIOSORD Risk Index Score, mean (SD)  40.4 (16)     26 (16.1) −0.895
 RIOSORD class, n (%)
  1 (0–24)  241 (17.1) 32 595 (50.1)  0.746
  2 (25–32)  151 (10.7)   9990 (15.3)  0.139
  3 (33–37)  166 (11.7)   6389 (9.8)  0.062
  4 (38–42)  195 (13.8)   5500 (8.4)  0.171
  5 (43–46)  151 (10.7)   3062 (4.7)  0.226
  6 (47–49)   98 (6.9)   1909 (2.9)  0.186
  7 (50–54)  164 (11.6)   2640 (4.1)  0.284
  8 (55–59)  106 (7.5)   1625 (2.5)  0.231
  9 (60–66)   81 (5.7)    934 (1.4)  0.233
  10 (≥ 67)   60 (4.2)    456 (0.7)  0.230
 Alcohol abuse  644 (45.8) 23 233 (36.7)  0.185
 Chronic kidney disease  142 (10)   3163 (4.9)  0.199
 Chronic hepatitis or cirrhosis  457 (32.3) 12 980 (19.9)  0.285
 Chronic pulmonary disease  506 (35.8) 12 929 (19.9)  0.362
 Tobacco use 1135 (80.3) 45 277 (69.5)  0.251
 Bipolar disorder or manic episodes  229 (16.2)   7921 (12.2)  0.116
 Schizophrenia or schizoaffective disorder   90 (6.4)   2861 (4.4)  0.088
 Sleep apnea  267 (18.9)   9910 (15.2)  0.098
Prescription drugs
 Opioid use, by formulation
  Immediate-release only  392 (27.7) 22 193 (34.1)  0.138
  Extended-release/long-acting only   47 (3.3)   1684 (2.6)  0.044
  Both  117 (8.3)   3006 (4.6)  0.150
 Average total daily morphine milligram equivalents, n (%)
  < 50 1225 (86.7) 59 872 (92)  0.171
  50 to < 100   97 (6.9)   3038 (4.7)  0.094
  ≥ 100   91 (6.4)   2190 (3.4)  0.143
 Select non-opioid drugs, n (%)
  Antidepressant  823 (58.2) 33 469 (51.4)  0.138
  Benzodiazepine  158 (11.2)   5033 (7.7)  0.118
  Stimulant   49 (3.5)   2223 (3.4)  0.003
  Muscle relaxant  285 (20.2) 10 302 (15.8)  0.113

Note: ‘Other’ race includes American Indian or Alaska Native, Asian, Multiple, Native Hawaiian or Other Pacific Islander. There were 1949 (3%) with decline toanswer/unknown/or missing race data in the no overdose group and 34 (2.4%) with decline to answer/unknown/or missing race data in the overdosegroup. There were 948 (1.5%) with multiple/decline to answer/unknown/or missing ethnicity data in the no overdose group and 22 (1.6%) with multiple/decline to answer/unknown/or missing ethnicity data in the overdose group. There were 1312 (2%) with missing marital status data in the no overdose group and six (0.4%) with missing marital status data in the overdose group. There were 415 (0.6%) missing rurality in the no overdose group and three (0.2%) with missing rurality in the overdose group. There were 307 (0.5%) with missing disability in the no overdose group and three (0.2%) with missing disability in the overdose group.

Abbreviations: SD = standard deviation; RIOSORD = Risk Index for Overdose and Serious Opioid-Induced Respiratory Depression.